EU/3/19/2187

About

On 25 July 2019, orphan designation EU/3/19/2187 was granted by the European Commission to Toleranzia AB, Sweden, for recombinant mutated extracellular domain of the human acetylcholine receptor subunit alpha1 for the treatment of myasthenia gravis.

Key facts

Active substance
Recombinant mutated extracellular domain of the human acetylcholine receptor subunit alpha1
Disease / condition
Treatment of myasthenia gravis
Date of first decision
25/07/2019
Outcome
Positive
EU designation number
EU/3/19/2187

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Toleranzia AB
Arvid Wallgrens Backe 20 8
Goteborgs Annedal
413 46 Goteborg
Sweden
Tel: +46(0)76 319 98 98
E-mail: notice@toleranzia.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating